FTC Rushes Patent Settlement Report In Push For Super Committee Action On "Pay-For-Delay"
The Federal Trade Commission rushed to press the data about the number of patent settlements between brand and generic companies in FY 2011 in an apparent effort to grab the attention of the Joint Select Committee on Deficit Reduction.
You may also be interested in...
Of the 140 brand-generic patent settlements in FY 2012, 40 contained both compensation to the generic manufacturer and a restriction on generic entry; FTC announces this record number as its suit against Watson goes to Supreme Court.
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.